{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:39:26Z","timestamp":1790343566540,"version":"4.1.0"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T00:00:00Z","timestamp":1440115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0135245","type":"journal-article","created":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T17:54:19Z","timestamp":1440179659000},"page":"e0135245","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":45,"title":["Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis"],"prefix":"10.1371","volume":"10","author":[{"given":"Maikel A.","family":"Farhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Carmine-Simmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald B.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan G.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,8,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1002\/cncr.24409","article-title":"Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma","volume":"115","author":"A Kapoor","year":"2009","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","article-title":"Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus","volume":"66","author":"D Del Bufalo","year":"2006","journal-title":"Cancer Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"M Guba","year":"2002","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.critrevonc.2010.07.018","article-title":"Sequential use of targeted agents in the treatment of renal cell carcinoma. [Review]","volume":"77","author":"TE Hutson","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","article-title":"Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma","volume":"32","author":"TE Hutson","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jb\/mvt047","article-title":"Evolutionarily conserved regulation of TOR signalling","volume":"154","author":"T Takahara","year":"2013","journal-title":"J Biochem (Tokyo)"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"M Laplante","year":"2012","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/emboj.2012.21","article-title":"Axl is essential for VEGF-A-dependent activation of PI3K\/Akt","volume":"31","author":"GX Ruan","year":"2012","journal-title":"EMBO J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/ATVBAHA.109.185918","article-title":"Rapamycin inhibition of the Akt\/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase","volume":"29","author":"Q Xue","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"D Benjamin","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-10-3126","article-title":"Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1\/mTORC2 inhibitors","volume":"71","author":"BL Falcon","year":"2011","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"ME Feldman","year":"2009","journal-title":"PLoS Biol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/BJ20090489","article-title":"Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)","volume":"421","author":"JM Garcia-Martinez","year":"2009","journal-title":"Biochem J"},{"key":"ref14","first-page":"1242","article-title":"Endothelial PI3 kinase-\u03b1 couples to VEGFR2, but is not required for eNOS activation","volume":"301","author":"QX Zhang","year":"2011","journal-title":"Am J Physiol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0076-6879(08)02004-1","article-title":"An optimized three-dimensional in vitro model for the analysis of angiogenesis","volume":"443","author":"MN Nakatsu","year":"2008","journal-title":"Methods Enzymol"},{"key":"ref16","first-page":"217","article-title":"The textbook of angiogenesis and lymphangiogenesis: Methods and applications","author":"A Zijlstra","year":"2012"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1083\/jcb.144.5.1019","article-title":"Protein Tyrosine Phosphatase-PEST Regulates Focal Adhesion Disassembly, Migration, and Cytokinesis in Fibroblasts","volume":"144","author":"A Angers-Loustau","year":"1999","journal-title":"The Journal of Cell Biology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"KE O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","article-title":"AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity","volume":"19","author":"S Chandarlapaty","year":"2011","journal-title":"Cancer Cell"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"DH Kim","year":"2002","journal-title":"Cell"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"DD Sarbassov","year":"2004","journal-title":"Curr Biol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.devcel.2006.10.007","article-title":"Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1","volume":"11","author":"DA Guertin","year":"2006","journal-title":"Dev Cell"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ncb1183","article-title":"Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive","volume":"6","author":"E Jacinto","year":"2004","journal-title":"Nat Cell Biol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.mvr.2011.05.002","article-title":"Focal adhesion kinase regulation of neovascularization","volume":"83","author":"KK Wary","year":"2012","journal-title":"Microvasc Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1083\/jcb.200109079","article-title":"Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling","volume":"157","author":"BP Eliceiri","year":"2002","journal-title":"J Cell Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-08-2057","article-title":"mTOR inhibitor RAD001 (everolimus) has antiangiogenic\/vascular properties distinct from a VEGFR tyrosine kinase inhibitor","volume":"15","author":"HA Lane","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e49456","DOI":"10.1371\/journal.pone.0049456","article-title":"Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin","volume":"7","author":"K Saito","year":"2012","journal-title":"PLoS ONE"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"G Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"RJ Motzer","year":"2010","journal-title":"Cancer"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/annonc\/mdn540","article-title":"Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery","volume":"19","author":"W Cacheux","year":"2008","journal-title":"Ann Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"JM Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1158\/1078-0432.CCR-12-0002","article-title":"Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients","volume":"18","author":"AW Griffioen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/annonc\/mdt130","article-title":"A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer","volume":"24","author":"T Powles","year":"2013","journal-title":"Ann Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccr.2006.07.003","article-title":"Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin","volume":"10","author":"TL Phung","year":"2006","journal-title":"Cancer Cell"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"RS Kerbel","year":"2008","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity","volume":"70","author":"CM Chresta","year":"2010","journal-title":"Cancer Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10549-012-2298-8","article-title":"Investigational drug MLN0128, a novel TORC1\/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models","volume":"136","author":"Y Gokmen-Polar","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/en.2012-1854","article-title":"Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice","volume":"154","author":"A Giubellino","year":"2013","journal-title":"Endocrinology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e54918","DOI":"10.1371\/journal.pone.0054918","article-title":"A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models","volume":"8","author":"H Zhang","year":"2013","journal-title":"PLoS ONE"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.1158\/1078-0432.CCR-13-3389","article-title":"Dual mTORC1\/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival","volume":"20","author":"HA Luchman","year":"2014","journal-title":"Clin Cancer Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"BS Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"VS Rodrik-Outmezguine-","year":"2011","journal-title":"Cancer Discov"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/MCB.14.3.1680","article-title":"Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src","volume":"14","author":"MD Schaller","year":"1994","journal-title":"Mol Cell Biol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1091\/mbc.10.10.3489","article-title":"Complex formation with focal adhesion kinase: A mechanism to regulate activity and subcellular localization of Src kinases","volume":"10","author":"MD Schaller","year":"1999","journal-title":"Mol Biol Cell"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/377539a0","article-title":"Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice","volume":"377","author":"D Ilic","year":"1995","journal-title":"Nature"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1158\/0008-5472.CAN-07-5869","article-title":"Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival","volume":"68","author":"PC McDonald","year":"2008","journal-title":"Cancer Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1379\/1466-1268(2003)8<37:IVRFVA>2.0.CO;2","article-title":"Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2\/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF","volume":"8","author":"B Masson-Gadais","year":"2003","journal-title":"Cell Stress Chaperones"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"39175","DOI":"10.1074\/jbc.M405493200","article-title":"Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities","volume":"279","author":"F Le Boeuf","year":"2004","journal-title":"J Biol Chem"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1091\/mbc.E07-05-0467","article-title":"Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase","volume":"18","author":"M Duval","year":"2007","journal-title":"Mol Biol Cell"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0135245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T02:51:33Z","timestamp":1540349493000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0135245"}},"subtitle":[],"editor":[{"given":"Magdalena","family":"Chrzanowska-Wodnicka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,8,21]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0135245","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,21]]}}}